A comprehensive, evidence-based exploration of metabolic and repurposed pharmaceuticals used in integrative oncology.Grounded in the metabolic theory of cancer,
Metabolic Drugs for Cancer challenges a strictly gene-centric model by emphasizing mitochondrial dysfunction, metabolic reprogramming, and immune evasion as central drivers of cancer progression.
This book translates complex biochemical and clinical concepts into clear, understandable language without sacrificing scientific rigor. The aim is to equip educated patients and practitioners with a meaningful understanding of why specific metabolic interventions are used, supporting informed decision-making and patient agency.
The manuscript systematically examines off-label and repurposed drugs, including:
- metformin
- statins
- dichloroacetate (DCA)
- 2-deoxy-D-glucose (2-DG)
- ivermectin
- mebendazole
- fenofibrate
- low-dose naltrexone
- hydroxychloroquine
- GLP-1 agonists
With all, it explains mechanisms of action and clinical relevance in a practical, integrated framework.
Rather than positioning metabolic oncology as an alternative to conventional care, the book emphasizes integration. It explores how metabolic strategies may complement chemotherapy, radiotherapy, immunotherapy, and supportive care when used appropriately, with attention to safety, contraindications, and quality-of-life considerations.
